KETEK (telithromycin), manufactured and sold by Sanofi-aventis U.S. recently decided, after prompting by the U.S. Food and Drug Administration, to include a revised black box warning and contraindication for myasthenia gravis patients. The new warning also removed the labels recommendation that KETEK be used in patients with chronic bronchitis (AECB) and acute bacterial sinusitis (ABS).
For more information on the revised KETEK black box warning see the “Dear HealthCare Professional Letter“:
@thumbnail.jpg "M. Brandon Smith")
A partner with Childers, Schlueter & Smith, LLC,, Brandon Smith has devoted his practice to pharmaceutical litigation, mass torts, products liability and serious personal injury. A frequent guest speaker at legal seminars all over the country—Brandon is focused on helping injured victims nationwide, however possible. Named a SuperLawyer again in 2019, he has also been called out as one of 10 Best Attorneys For Georgia by the American Institute Of Personal Injury Attorneys and a Top 100 Lawyer in Georgia by the National Trial Lawyers in 2019.
Comments for this article are closed.